Views & Analysis What pharma can do to win in virtual Early data indications from the first virtual congresses shows big changes are needed.
News Regeneron's three-monthly gMG drug Livsayis cleared by FDA Regeneron has joined the crowded gMG market with an siRNA-based therapy, Livsayis, that only needs to be dosed four times a year.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.